Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 3 Part 1：r/r B-cell Malignancies 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Hematologic Neoplasms 1

Interventions

Rituximab 101 Cyclophosphamide 51 Prednisone 32 Doxorubicin 32 Vincristine 31 Gemcitabine 29 Lenalidomide 27 Oxaliplatin 22 Bendamustine Hydrochloride 19 ibrutinib 16 fludarabine 16 tafasitamab 12 polatuzumab vedotin 12 venetoclax 11 tisagenlecleucel 11 obinutuzumab 11 loncastuximab tesirine 9 Etoposide 9 zanubrutinib 8 Prednisolone 8 Injections 8 Ifosfamide 8 Carboplatin 8 selinexor 7 pembrolizumab 7 durvalumab 7 axicabtagene ciloleucel 7 Dexamethasone 7 tazemetostat 6 parsaclisib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, Large B-Cell, Diffuse × orelabrutinib × Clear all

NCT05234684 2024-02-07

BELIEVE-01

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3 Unknown

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡